Denali Therapeutics Inc. SEC filings DNLI
Denali Therapeutics Inc. has 789 filings in SEC EDGAR's recent list, going back to Sep 8, 2017. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | Mar 1, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 7, 2019 | — |
| CORRESP | Letter to the SEC | Sep 11, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 16, 2019 | — |
| CORRESP | Letter to the SEC | Jul 16, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2019 | — |
| CT ORDER | Filing | Mar 25, 2019 | — |
| CT ORDER | Filing | Feb 21, 2019 | — |
| CT ORDER | Filing | Nov 19, 2018 | — |
| CT ORDER | Filing | Jul 17, 2018 | — |
| CT ORDER | Filing | Dec 8, 2017 | — |
| EFFECT | Filing | Dec 7, 2017 | — |
| CORRESP | Letter to the SEC | Dec 4, 2017 | — |
| CORRESP | Letter to the SEC | Dec 4, 2017 | — |
| CERTNAS | Auto-generated paper document | Dec 1, 2017 | — |
| 8-A12B | Form 8-a12b | Nov 30, 2017 | — |
| CORRESP | Letter to the SEC | Nov 27, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2017 | — |
| CORRESP | Letter to the SEC | Nov 15, 2017 | — |
| CORRESP | Letter to the SEC | Nov 13, 2017 | — |
| DRS/A | Filing | Oct 27, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2017 | — |
| DRSLTR | Filing | Oct 13, 2017 | — |
| DRS/A | Filing | Oct 13, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 6, 2017 | — |
| DRS | Filing | Sep 8, 2017 | — |
Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- DNLI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1714899
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.